Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
52.47%
Operating Margin
34.95%
Net Margin
31.28%
Efficiency Metrics
Revenue per Expense Ratio
1.54
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
-5.89%
Income Tax Rate
-697,600,000,000.0%
EPS
4.2100000000
Balance Sheet Analysis
Current Ratio
0.53
Cash Ratio
0.08
Working Capital
$-2.71B
Debt to Equity
0.55
Debt to Assets
28.58%
Equity Ratio
51.93%
Cash Flow Analysis
Operating Cash Flow Ratio
32.95%
Free Cash Flow Ratio
13.05%
CapEx to Revenue
19.90%
Dividends Paid
$707.00M
Stock Buybacks
No buybacks
Total Shareholder Returns
$707.00M
Cash Position Change
2.88%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
42.44%
Net Income
11.66%
EPS
11.38%
Operating Income
-8.53%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-100.00%
Operating Cash Flow
-0.12%
Free Cash Flow
-36.63%
Balance Sheet Health
Assets
8.72%
Debt
16.22%
Book Value per Share
8.74%
Inventory
40.85%
Shareholder Returns
Dividends per Share
-0.30%
Shares Outstanding
0.30%
Long Term Trends
3Y Revenue/Share
18.27%
5Y Revenue/Share
31.45%
3Y Dividend/Share
9.96%
5Y Dividend/Share
55.62%